Stockscreener 앱 받기
0.2985
6.78%
-0.0217
전일 마감가:
$0.3202
열려 있는:
$0.3204
하루 거래량:
374.61K
Relative Volume:
0.15
시가총액:
$7.70M
수익:
-
순이익/손실:
$-29.80M
주가수익비율:
-0.2508
EPS:
-1.19
순현금흐름:
$-25.19M
1주 성능:
-14.22%
1개월 성능:
-13.78%
6개월 성능:
-42.72%
1년 성능:
-78.05%
1일 변동 폭
$0.2625
$0.3444
1주일 범위
$0.2625
$0.359
52주 변동 폭
$0.25
$1.45
센세이 바이오테라 Stock (SNSE) Company Profile
명칭
Sensei Biotherapeutics Inc
전화
(240) 243-8000
주소
1405 RESEARCH BLVD, SUITE 125, ROCKVILLE
SNSE을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SNSE
Sensei Biotherapeutics Inc
|
0.3055 | 8.57M | 0 | -29.80M | -25.19M | -1.19 |
|
ONC
Beigene Ltd Adr
|
239.00 | 23.78B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
433.79 | 108.15B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.2548 | 43.44M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
597.31 | 61.69B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
73.60 | 5.72B | 0 | -153.72M | -103.81M | -2.00 |
센세이 바이오테라 Stock (SNSE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-05-14 | 개시 | Stephens | Overweight |
| 2021-07-01 | 다운그레이드 | Berenberg | Buy → Hold |
| 2021-06-29 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2021-03-01 | 개시 | Berenberg | Buy |
| 2021-03-01 | 개시 | Citigroup | Buy |
| 2021-03-01 | 개시 | Oppenheimer | Outperform |
| 2021-03-01 | 개시 | Piper Sandler | Overweight |
모두보기
센세이 바이오테라 주식(SNSE)의 최신 뉴스
Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) Shares Sold by Renaissance Technologies LLC - Defense World
Sensei Biotherapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Sensei (SNSE) Reports Encouraging Clinical Results in Recent Qua - GuruFocus
Sensei Biotherapeutics Reports Promising Q1 2025 Results - TipRanks
Sensei Biotherapeutics Reports First Quarter 2025 Financial Resu - GuruFocus
Sensei (SNSE) Reports Encouraging Clinical Results in Recent Quarter | SNSE Stock News - GuruFocus
Sensei Biotherapeutics Reports First Quarter 2025 Financial Results and Updates on Clinical Progress - The Manila Times
Sensei Biotherapeutics Reports First Quarter 2025 Financial Results and Updates on Clinical Progress | SNSE Stock News - GuruFocus
Sensei Bio's Cancer Drug Achieves Breakthrough: 3X Better Response in PD-L1 Resistant Patients - Stock Titan
Sensei Biotherapeutics Inc expected to post a loss of 22 cents a shareEarnings Preview - TradingView
SEC Form DEF 14A filed by Sensei Biotherapeutics Inc. - Quantisnow
Penny Stocks To Add to Your WatchlistMarch 30th - MarketBeat
Sensei Biotherapeutics to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference - The Manila Times
Best Penny Stocks To Follow NowMarch 28th - MarketBeat
Promising Penny Stocks To ResearchMarch 29th - MarketBeat
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Sensei Biotherapeutics stock hits 52-week low at $0.34 By Investing.com - Investing.com South Africa
Sensei Biotherapeutics stock hits 52-week low at $0.34 - Investing.com
HC Wainwright Reiterates Buy Rating for Sensei Biotherapeutics (NASDAQ:SNSE) - Defense World
Sensei Biotherapeutics (NASDAQ:SNSE) Stock Price Expected to Rise, Oppenheimer Analyst Says - Defense World
Sensei Biotherapeutics (NASDAQ:SNSE) Price Target Raised to $4.00 at Oppenheimer - Armenian Reporter
Sensei Biotherapeutics Reports Promising 2024 Results - TipRanks
Sensei Biotherapeutics (SNSE) Reports Annual Loss and Decline in Cash Reserves - GuruFocus
Sensei stock holds Buy rating, $4 target from H.C. Wainwright By Investing.com - Investing.com Australia
Sensei Rockets on FY ’24 Results - Baystreet.ca
Sensei Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024 - Marketscreener.com
Sensei Biotherapeutics Reports Favorable Initial Clinical Activity Data For Solnerstotug In Resistant Tumors - Benzinga
Sensei Biotherapeutics price target raised to $4 from $3.50 at Oppenheimer - TipRanks
Oppenheimer Adjusts Price Target on Sensei Biotherapeutics to $4 From $3.50, Maintains Outperform Rating - Marketscreener.com
Sensei Biotherapeutics reports FY24 EPS ($1.20) vs ($1.22) last year - TipRanks
Sensei stock holds Buy rating, $4 target from H.C. Wainwright - Investing.com
Sensei Biotherapeutics Inc Cash Runway Into Q2 Of 2026 - MarketScreener
Sensei Biotherapeutics, Inc. SEC 10-K Report - TradingView
Sensei Biotherapeutics Reports Full Year 2024 Financial Results and Update on Clinical Progress - GlobeNewswire
Breakthrough: Sensei's Cancer Drug Triples Response Rate in Hard-to-Treat Tumors - Stock Titan
Sensei Biotherapeutics announces initial results from solnerstotug trial portion - TipRanks
Sensei Biotherapeutics Reports Favorable Preliminary Dose Expansion Data For Solnerstotug In PD-(L)1 Resistant Tumors - Marketscreener.com
Sensei Biotherapeutics : Company Presentation March 2025 - Marketscreener.com
Sensei Biotherapeutics Reports Favorable Preliminary Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors - GlobeNewswire
Revolutionary Cancer Treatment Triples Response Rate in Hard-to-Treat Tumors: Clinical Trial Results Revealed - Stock Titan
Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) Sees Large Drop in Short Interest - Defense World
Sensei Biotherapeutics Stock Price, Quotes and Forecasts | NASDAQ:SNSE - Benzinga
Sensei Biotherapeutics Inc expected to post a loss of 28 cents a shareEarnings Preview - TradingView
Sensei Biotherapeutics (SNSE) to Release Quarterly Earnings on Wednesday - Defense World
What Makes Sensei Biotherapeutics (SNSE) a New Buy Stock - MSN
A stock that deserves closer examination: Sensei Biotherapeutics Inc (SNSE) - US Post News
Sensei Biotherapeutics to Participate in Oppenheimer’s 35th Annual Healthcare Life Sciences Conference - GlobeNewswire
Sensei Biotherapeutics to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference - The Manila Times
Biotech Spotlight: Sensei Bio Takes Center Stage at Major Healthcare Conference - StockTitan
센세이 바이오테라 (SNSE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.40%
8.08%
자본화:
|
볼륨(24시간):